{
    "clinical_study": {
        "@rank": "46788", 
        "arm_group": {
            "arm_group_label": "INC280", 
            "arm_group_type": "Experimental", 
            "description": "The protocol consists of two independent parts (Dose-Determining Part and Dose Expansion Part). Approximately 6 patients will be treated with INC280 300 mg twice a day in the Dose-Determining Part. Approximately 50 patients will be treated with INC280 in the Dose Expansion Part. The dose for the Expansion Part can be lower, equal or higher than in the Dose-Determining Part will be determined after the Dose Determining Part at the dose decision analysis."
        }, 
        "brief_summary": {
            "textblock": "This study is to find out if INC280 is safe and has beneficial effects in patients with\n      advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway."
        }, 
        "brief_title": "Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Hepatocellular Carcinoma With c-MET Dysregulation", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed as a Phase II, single arm, open-label, multicenter study to evaluate\n      the safety and efficacy of INC280 as first-line treatment in patients with advanced\n      hepatocellular carcinoma (HCC) who are not eligible for or had disease progression after\n      surgical or locoregional therapies, with c- MET dysregulation.\n\n      The study includes a Dose-Determining Part and a Dose Expansion Part. Pharmacokinetic and\n      safety profiles of INC280 in the setting of liver dysfunction will be determined in the\n      Dose-Determining Part.  The Dose Expansion Part will start when the appropriate dose for\n      patients with liver dysfunction is determined based on pharmacokinetics (PK) and safety data\n      from the Dose-Determining Part and other INC280 ongoing clinical studies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed c-MET pathway dysregulation.\n\n          -  Advanced hepatocellular carcinoma which could not be suitable for treatment with\n             locoregional therapies or has progressed following locoregional therapy.\n\n          -  Measurable disease as determined by RECIST version 1.1.\n\n          -  Current cirrhotic status of Child-Pugh class A with no encephalopathy.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status < or = 2.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Received any prior systemic chemotherapy or molecular-targeted therapy for\n             hepatocellular carcinoma such as sorafenib.\n\n          -  Previous treatment with c-MET inhibitor or hepatocyte growth factor targeting\n             therapy.\n\n          -  Previous local therapy completed less than 4 weeks prior to dosing and, if present,\n             any acute toxicity > grade 1.\n\n          -  Known active bleeding (e.g. bleeding from gastro-intestinal ulcers or esophageal\n             varices) within 2 months prior to screening or with history or evidence of inherited\n             bleeding diathesis or coagulopathy.\n\n          -  Clinically significant venous or arterial thrombotic disease within past 6 months.\n\n          -  History of acute or chronic pancreatitis, surgery of pancreas or any risk factors\n             that may increase risk of pancreatitis.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737827", 
            "org_study_id": "CINC280X2201"
        }, 
        "intervention": {
            "arm_group_label": "INC280", 
            "description": "INC280 will be administered orally and continuously on a twice a day dosing schedule.", 
            "intervention_name": "INC280", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "INC280, advanced hepatocellular carcinoma, c-MET pathway dysregulation", 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Khon Kaen", 
                        "country": "Thailand", 
                        "zip": "40002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Hong Kong", 
                "Singapore", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open Label, Single Arm, Multicenter Study of INC280 Administered Orally in Adults With Advanced Hepatocellular Carcinoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "Hong Kong: Department of Health", 
                "Singapore: Health Sciences Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to progression is the time from the date of baseline evaluation to the date of the first documented radiological confirmation of disease progression or death due to underlying cancer.", 
            "measure": "Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1", 
            "safety_issue": "No", 
            "time_frame": "baseline, 6 weeks up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737827"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Response Rate is defined as the proportion of patients with a best overall response of complete response or partial response at any time on study per RECIST version 1.1.", 
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 6 weeks up to 6 months"
            }, 
            {
                "description": "Progression free survival is defined as the time from date of first study treatment intake to the date of the first radiologically documented progression or death due to any cause or initiation of new antineoplastic therapy. if a patient has not had an event, progression free survival is censored at the date of last adequate tumor assessment.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "date of treatment, every 6 weeks up to 6 months"
            }, 
            {
                "description": "Overall survival is defined as the time from date of first study treatment intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From date of treatment until death, average 10.7 months"
            }, 
            {
                "description": "Disease control rate is defined as the proportion of patients with a best overall response of complete response, partial response or stable disease at any time on study per RECIST version 1.1", 
                "measure": "Disease Control Rate", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 6 weeks up to 6 months"
            }, 
            {
                "description": "Frequency, duration and severity of adverse events.", 
                "measure": "Safety: adverse events, serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline until 30 days post study treatment"
            }, 
            {
                "description": "Change from baseline values.", 
                "measure": "Safety: hematology and chemistry values, vital signs, electrocardiograms", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline until end of treatment, average 6 months from baseline"
            }, 
            {
                "description": "Tolerability will be assessed by summarizing the number of dose interruptions, dose reductions and dose intensity.", 
                "measure": "Tolerability of study drug", 
                "safety_issue": "Yes", 
                "time_frame": "From date start of treatment until end of treatment, average 6 months from baseline"
            }, 
            {
                "description": "Plasma concentration of INC280 versus time profiles.  AUC=Area Under the Curve", 
                "measure": "Plasma pharmacokinetic parameter: AUC0-t", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 15 and 16 of Cycle 1, Day 1 of Cycle 2 and Cycle 3"
            }, 
            {
                "description": "Change from baseline", 
                "measure": "Alpha-fetoprotein", 
                "safety_issue": "No", 
                "time_frame": "baseline, every 6 weeks up to 6 months"
            }, 
            {
                "description": "Change from baseline", 
                "measure": "Soluble c-MET", 
                "safety_issue": "No", 
                "time_frame": "baseline, Cycle 1 Days 1, 2 and 15, then Day 1 of each cycle until end of treatment"
            }, 
            {
                "description": "Change from baseline", 
                "measure": "Soluble Hepatocyte Growth Factor", 
                "safety_issue": "No", 
                "time_frame": "baseline, Cycle 1 Days 1, 2 and 15, then Day 1 of each cycle until end of treatment"
            }, 
            {
                "description": "Plasma concentration of INC280 versus time profiles", 
                "measure": "Plasma pharmacokinetic parameter: CL/F", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 15 and 16 of Cycle 1, Day 1 of Cycle 2 and Cycle 3"
            }, 
            {
                "description": "Plasma concentration of INC280 versus time profiles. Cmax = Maximum concentration", 
                "measure": "Plasma pharmacokinetic parameter: Cmax", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 15 and 16 of Cycle 1, Day 1 of Cycle 2 and Cycle 3"
            }, 
            {
                "description": "Plasma concentration of INC280 versus time profiles. Tmax =Time to reach maximum concentration", 
                "measure": "Plasma pharmacokinetic parameter: Tmax", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 15 and 16 of Cycle 1, Day 1 of Cycle 2 and Cycle 3"
            }, 
            {
                "description": "Plasma concentration of INC280 versus time profiles", 
                "measure": "Plasma pharmacokinetic parameter: T1/2", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 15 and 16 of Cycle 1, Day 1 of Cycle 2 and Cycle 3"
            }, 
            {
                "description": "Plasma concentration of INC280 versus time profiles", 
                "measure": "Plasma pharmacokinetic parameter: Racc", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 15 and 16 of Cycle 1, Day 1 of Cycle 2 and Cycle 3"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}